Epitalon (also written Epithalon or Epithalone) is a synthetic four-amino-acid peptide — Ala-Glu-Asp-Gly, abbreviated AEDG — designed to reproduce the activity of Epithalamin, a peptide extract originally isolated from bovine pineal gland tissue [1]. It sits at the center of the "peptide bioregulator" research program built over five decades by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, and it has been studied for proposed effects on telomerase activity, tumor incidence in animals, circadian melatonin rhythm, and, via the parent extract, mortality in elderly human cohorts. One point needs to be stated plainly, and it will be repeated throughout this page: the published evidence base for Epitalon and Epithalamin comes almost entirely from one research network — Khavinson's institute and its closest collaborators — much of it published in Russian-language journals (frequently with only an English abstract), spanning the 1990s through the 2000s, with independent replication essentially limited to a single 2025 in vitro study. Readers should treat the findings below as observations reported largely by one laboratory group, not as independently established effects — and should note carefully, at every step, whether a given result was obtained with Epithalamin (the crude pineal extract) or Epitalon (the synthetic tetrapeptide), since the two are related but not identical substances and the literature does not always keep them cleanly separated.
What Is Epitalon?
Epithalamin is a polypeptide complex extracted from the pineal glands of cattle, developed and studied in the Soviet Union beginning in the 1970s as part of a broader research program that produced tissue-specific extracts intended to act on their organ of origin (Thymalin from thymus, Cortexin from cerebral cortex, and others) [1]. Epitalon is the synthetic tetrapeptide that Khavinson's group later identified and manufactured as a stable, defined analog intended to reproduce Epithalamin's reported activity without the batch variability of an animal-tissue extract [1].
The underlying concept — sometimes called "peptide bioregulation" — holds that short peptides derived from a given tissue can regulate gene expression preferentially in that same tissue type, and that supplying such peptides can help "restore" youthful patterns of gene activity as an organism ages. A 2025 structural and pharmacological review of Epitalon, produced independently of Khavinson's group by researchers at the Medical University of Warsaw, describes a substantial volume of in vitro, in vivo, and in silico research on the compound over roughly 25 years, but notes that despite this volume, physico-chemical and structural characterization of the peptide itself "remains quite limited," and states plainly that it "remains uncertain whether [the reported effects] are the sole mechanisms of action of this compound" [1]. That review is a useful anchor point precisely because it is one of the few substantive publications on Epitalon not authored by the originating institute.
Mechanism of Action (Proposed)
No specific cell-surface receptor for Epitalon has been identified, and the literature instead proposes an epigenetic mode of action operating largely from within the cell nucleus.
Gene expression and chromatin interaction. The central hypothesis from Khavinson's group, laid out in a 2021 systematic review, is that short peptides of 2–7 amino acid residues can penetrate cell nuclei and nucleoli and interact directly with nucleosomes, histone proteins, and single- and double-stranded DNA, including sequence recognition within gene promoter regions [2]. The same review proposes that such peptides can influence DNA methylation status — an epigenetic mechanism governing gene activation or repression — and speculates that short peptides may have been among the earliest evolutionary signaling molecules for template-directed synthesis [2]. This is a mechanistic framework built almost entirely on the originating group's own body of work.
Telomerase induction. A separate, frequently cited mechanistic claim is that Epitalon reactivates the telomerase gene. In a 2003 experiment, addition of Epithalon peptide to a culture of telomerase-negative human fetal fibroblasts was reported to induce expression of the telomerase catalytic subunit, measurable telomerase enzymatic activity, and telomere elongation, which the authors interpreted as evidence the peptide could reactivate a normally silent telomerase gene in somatic cells [3].
Other proposed effects. The 2025 Warsaw review also catalogs additional reported activities — a direct influence on melatonin synthesis, altered interleukin-2 mRNA levels, modulation of the mitogenic activity of murine thymocytes, and enhanced activity of acetylcholinesterase, butyrylcholinesterase, and telomerase — while explicitly flagging that it is not established whether these represent the complete mechanistic picture [1]. As with BPC-157 and other bioregulator-family peptides, the breadth of proposed effects across seemingly unconnected biological systems is itself something that warrants independent, skeptical scrutiny rather than acceptance at face value.
Research Findings by Area
Everything below describes preclinical (cell-culture or animal) research, or an aging human cohort study with an extract rather than the synthetic peptide. None of it constitutes a controlled clinical trial of Epitalon in humans.
Telomere length and telomerase activity (in vitro)
The foundational finding is the 2003 Khavinson study described above: exposure of telomerase-negative human fetal fibroblasts to Epithalon peptide was associated with telomerase catalytic-subunit expression, enzymatic activity, and telomere elongation [3]. For roughly two decades, this observation was not independently repeated by any group outside the originating institute.
That changed in September 2025, when researchers at Brunel University London — with no institutional or authorship connection to Khavinson's group — published a study treating human breast cancer cell lines (21NT, BT474) alongside normal epithelial and fibroblast cells with Epitalon, then measuring hTERT mRNA expression, telomerase activity, and telomere length by qPCR and immunofluorescence [4]. They reported dose-dependent telomere length extension in normal cells attributable to hTERT and telomerase upregulation, and a distinct, telomerase-independent mechanism — activation of the Alternative Lengthening of Telomeres (ALT) pathway — driving telomere extension specifically in the cancer cell lines, with only a minor ALT signal in normal cells [4]. A correction to this article was published by the journal in November 2025 [5]. This Brunel study is, as far as this review identified, the clearest instance of independent replication anywhere in the Epitalon literature — but it is a single in vitro study, examines molecular biology rather than any organismal outcome, and its finding that Epitalon can activate telomere-lengthening machinery specifically in cancer cells is a complicating result, not a straightforwardly reassuring one; telomere maintenance is itself an established feature that many cancers rely on to sustain unlimited division.
Animal studies: tumor incidence and carcinogenesis
A cluster of rodent studies from Khavinson's institute, most conducted jointly with Vladimir Anisimov's laboratory at the N.N. Petrov Research Institute of Oncology in St. Petersburg, reports various tumor-related associations with Epitalon administration:
- In female Swiss-derived SHR mice followed from age 3 months until natural death, Epitalon did not affect body weight, mean lifespan, or total spontaneous tumor incidence — but was associated with a 6.0-fold reduction in leukemia development and 12–13% increases in maximum and last-decile survivor lifespan versus saline controls [6].
- In one-year-old female C3H/He mice, Epitalon was associated with fewer malignant tumor-bearing animals and less metastasis from spontaneous reproductive-organ tumors (found in 3 of 9 control mice, none of the treated mice) [7]. Run at the Hebrew University of Jerusalem with Anisimov as co-author, this is one of the few studies with any institutional distance from St. Petersburg — though senior authorship still overlaps the originating network.
- In rats exposed to the colon carcinogen 1,2-dimethylhydrazine (DMH), Epitalon was associated with fewer colon tumors per rat and reduced tumor incidence and multiplicity in the ascending and descending colon versus controls [8].
- In HER-2/neu transgenic mice, which spontaneously develop mammary tumors, Epitalon was associated with a reduced cumulative tumor count, smaller lung metastases, and a 3.7-fold reduction in HER-2/neu mRNA expression versus controls; a comparator peptide (Vilon) tested in the same experiment performed worse than control [9].
These are consistent, repeatedly reported associations, but from a tightly overlapping author network — no fully independent lab has replicated the organismal carcinogenesis findings.
Circadian melatonin restoration
Aging is associated with reduced nighttime and average daily plasma melatonin and a blunted circadian amplitude, reflecting declining pineal gland function. In a study of aged monkeys (housed at a primate research center in the former Soviet Union) and elderly human subjects, both Epithalamin (the extract) and Epitalon (the synthetic tetrapeptide) were reported to restore nighttime melatonin release and normalize the plasma melatonin circadian rhythm in old monkeys, while producing no detectable change in young monkeys; in elderly people with reduced pineal function, the preparations were associated with increased nighttime melatonin [10]. This study, published in Russian with an English abstract, again originates from Khavinson's collaborator network.
Human elderly-cohort studies (Epithalamin, not Epitalon)
The most-cited human data in this literature does not involve the synthetic tetrapeptide Epitalon at all — it involves Epithalamin, the pineal extract. Researchers from the St. Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences followed 266 elderly and older adults for 6–8 years, with Thymalin (a thymic extract) and/or Epithalamin administered during the first 2–3 years of observation. The same dataset was reported in a Russian-language 2002 publication [11] and an English-language 2003 publication [12] with essentially identical figures, which should be read as one study appearing in two venues rather than two independent confirmations. Reported associations included a 2.0–2.4-fold decrease in acute respiratory disease incidence and reduced rates of ischemic heart disease, hypertension, osteoarthrosis, and osteoporosis compared with controls, alongside mortality reductions of 1.6–1.8-fold in the Epithalamin group, 2.0–2.1-fold in the Thymalin group, and 2.5-fold in patients receiving both; a subgroup given both preparations annually for six years showed a 4.1-fold mortality reduction relative to control [11,12].
These are striking figures, and they are also the weakest-documented part of the entire literature from a methodological standpoint: the published abstracts do not describe randomization procedure, allocation concealment, blinding, a prespecified statistical analysis plan, or loss-to-follow-up handling, and the trial has not been independently repeated by any group outside the original Russian-Ukrainian gerontology network in the more than two decades since publication. It is also, again, a study of the extract rather than the synthetic peptide that is the primary subject of this page.
Limitations and Open Questions
Single-laboratory concentration. With the exception of one 2025 in vitro study from Brunel University London [4,5], every finding summarized above originates from Vladimir Khavinson's institute or its direct, long-running collaborators (principally Anisimov's oncology laboratory in St. Petersburg, with occasional co-authors in Israel, Italy, and Ukraine). Much of the underlying literature is published in Russian-language journals with only English abstracts available, which limits independent scrutiny of methods. Readers should weight this literature accordingly — the consistency of results across decades of publications from the same network is not the same thing as independent confirmation.
Epithalamin/Epitalon conflation. The extract (Epithalamin) and the synthetic tetrapeptide (Epitalon) are related but distinct substances, evaluated in different studies, and the literature frequently discusses them side by side or attributes findings from one to the other in secondary sources. The human mortality and disease-incidence data summarized above come from the extract, not the synthetic peptide, and should not be read as clinical evidence for Epitalon specifically.
No controlled human trials of Epitalon. There are no published randomized, blinded, placebo-controlled human trials of the synthetic Epitalon tetrapeptide for any indication. The 266-patient cohort work involved Epithalamin and Thymalin, was conducted and reported entirely by the originating research network, and lacks the methodological detail needed for independent appraisal.
Independent replication is essentially absent. Outside the single 2025 Brunel telomere study — which examined molecular biology in cell culture, not organismal outcomes, and reported a complicating finding (telomerase-independent telomere extension via ALT specifically in cancer cell lines) [4,5] — no organismal effect described in this article (tumor incidence, melatonin restoration, mortality) has been repeated by a laboratory independent of Khavinson's network.
Mechanistic uncertainty. No specific receptor has been identified, and even the 2025 independent review of the compound states that it remains uncertain whether the proposed mechanisms (melatonin synthesis effects, cytokine mRNA modulation, enzyme activation, telomerase induction) represent the full picture [1].
Regulatory status. Epitalon is not an approved drug anywhere. A Pharmacy Compounding Advisory Committee (PCAC) meeting held July 23–24, 2026 considered Epitalon (free base and acetate) for potential inclusion on the FDA's Section 503A Bulk Drug Substances List, for a proposed use in insomnia (see FDA's PCAC meeting page). Outlets covering the meeting reported FDA staff briefing materials described the nominated peptides, including Epitalon, as not well-characterized, lacking sufficient human safety and effectiveness data, and carrying unassessed immunogenicity risk. The committee's vote is a non-binding recommendation; any listing decision rests with further HHS action. Epitalon remains unapproved and, by FDA's own account, uncharacterized.
Frequently Asked Questions
Is Epitalon the same thing as Epithalamin? No. Epithalamin is a polypeptide complex extracted from bovine pineal gland tissue; Epitalon is a defined synthetic tetrapeptide (Ala-Glu-Asp-Gly) designed to reproduce its reported activity [1]. Much of the human cohort data discussed in gerontology literature involves Epithalamin, not the synthetic peptide.
Has Epitalon been tested in humans in a controlled trial? Not in any published randomized controlled trial specific to the synthetic tetrapeptide. The human data most often cited involves Epithalamin and Thymalin in a 266-person cohort followed for 6–8 years by the originating Russian-Ukrainian group, with abstracts that omit standard trial-quality details like blinding or allocation concealment [11,12].
What is the strongest evidence for Epitalon? Probably the 2025 independent study from Brunel University London, which found dose-dependent telomere length extension and hTERT/telomerase upregulation in normal human cell lines after Epitalon exposure [4,5]. It matters mainly because it is the one clearly independent replication in the entire literature — still a single in vitro study, and one that also found a telomerase-independent extension mechanism (ALT) activated specifically in the cancer cell lines tested, which complicates any simple "good for cells" narrative.
Does Epitalon prevent cancer? Animal studies from Khavinson's and Anisimov's labs have reported reduced tumor multiplicity, metastasis, or incidence of specific tumor types (leukemia, chemically induced colon tumors, HER-2/neu-driven mammary tumors) in several rodent models, while one of those same studies found no effect on total spontaneous tumor incidence [6,7,8,9]. These are preclinical, single-network findings, not an established cancer-preventive effect in humans.
Why does the same human study seem to be cited twice? Because it effectively is the same study. The 266-patient Thymalin/Epithalamin cohort was published in a Russian-language journal in 2002 and again in an English-language journal in 2003, by the same two authors, reporting essentially identical figures [11,12]. Citing both is standard practice in this literature, but readers should recognize it as one dataset, not two independent confirmations.
Is Epitalon FDA approved? No. It is not an approved drug for any indication. As of mid-2026, it was under advisory-committee review for a narrower question — whether it should be added to the FDA's list of substances eligible for pharmacy compounding under Section 503A — a review process, not an approval, and one where FDA's own briefing materials reportedly raised safety-characterization concerns.
References
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci. 2025;26(6):2691. doi:10.3390/ijms26062691 — PMID: 40141333
- Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053 — PMID: 34834147
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. doi:10.1023/a:1025493705728 — PMID: 12937682
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. doi:10.1007/s10522-025-10315-x — PMID: 40908429
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;27(1):1. doi:10.1007/s10522-025-10326-8 — PMID: 41240216
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. doi:10.1023/a:1025114230714 — PMID: 14501183
- Kossoy G, Anisimov VN, Ben-Hur H, Kossoy N, Zusman I. Effect of the synthetic pineal peptide epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257. PMID: 16634527
- Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Lett. 2002;183(1):1-8. doi:10.1016/S0304-3835(02)00090-3 — PMID: 12049808
- Anisimov VN, Khavinson VK, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. doi:10.1002/ijc.10570 — PMID: 12209581
- Korkushko OV, Lapin BA, Goncharova ND, et al. [Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people]. Adv Gerontol. 2007;20(1):74-85. PMID: 17969590
- Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. PMID: 12577695
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363
This article is an educational summary of published research. It is not medical advice, and it does not describe, endorse, or recommend any use of Epitalon in humans. Epitalon is not an approved drug. Products referenced on this site are sold for laboratory research use only.
